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Background: CRB1 mutations are reported as cause of severe congenital and early-onset retinal dystrophies (EORD)
with different phenotypic manifestations, including Leber congenital amaurosis (LCA), retinitis pigmentosa (RP) and
cone-rod dystrophies. Comprehensive mutational scanning of the whole gene has been only performed in few
cohorts, mainly in LCA patients. Here, we aimed investigating the real prevalence of CRB1 mutations in the Spanish
population by extensive screening of CRB1 mutations in a large cohort of LCA and EORP cases.
Methods: This report integrates data from previous studies on CRB1 defects in our Spanish cohort of LCA and
early-onset RP (EORP) with new findings from a comprehensive mutational screening of the whole gene. The
molecular tools used include mutation genotyping arrays, whole-genome homozygosity mapping, an optimized
high-resolution melting (HRM) analysis and Sanger sequencing.
Results: A large clinically well-characterized cohort of 404 Spanish cases was studied, 114 of which suffered from
LCA and 290 from EORP. This study reveals that 11% of Spanish patients carried mutations in CRB1, ranging from
9% of EORP to 14% of LCA cases. More than three quarters of the mutations identified herein have been first
described in this Spanish cohort, 13 of them are unreported new variants and 13 had been previously reported in
our previous studies.
Conclusions: This work provides a wide spectrum of CRB1 mutations in the Spanish EORD patients and evidences
the major role of CRB1 as causal gene in the Spanish EORP patients. It is noteworthy that a high rate of private
mutations only described in our cohort has been found so far. To our knowledge, this study represents the most
complete mutational screening of CRB1 in a Spanish LCA and EORP cohort, allowing us to establish gene-specific
frequencies and to provide a wide spectrum of CRB1 mutations in the Spanish population.
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Mutations in the human Crumbs homolog 1 (CRB1, MIN
#604210) gene lead to severe congenital and early-onset
retinal dystrophies (EORD) with a wide range of clinical
manifestations including Leber congenital amaurosis (LCA,
MIN #613835), early-onset Retinitis Pigmentosa (EORP)
with or without preserved para-arteriolar retinal pigment
epithelium (PPRPE; MIN #600105), Coats-like exudative
vasculopathy, and juvenile cone-rod dystrophies [1-5]. The
prevalence of CRB1 mutations varies widely depending on
the clinical phenotype and the cohort studied, ranging be-
tween 7% in EORD patients [6], 10% in LCA patients [7],
31% in RP patients with Coats-like exudative vasculopathy
and 66% in RP patients with PPRPE [8]. CRB1 mutations
are rare (2%) in RP without signs of PPRPE or Coats-like
exudative vasculopathy [8].
The CRB1 gene, located in 1q31, contains 12 exons and
an alternative splicing at the 3’ end, encoding two different
isoforms of 1,376 and 1,406 amino acids [9]. Both proteins
have a signal peptide sequence, 19 epidermal growth factor
(EGF)-like domains, 3 laminin A globular (AG)-like do-
mains, and the longer isoform also contains additional
transmembrane and cytoplasmatic domains [9]. In total,
over 150 different mutations have been identified, mainly
located in the extracellular domain [10], and so, suggesting
to play an important role probably by interacting with un-
known proteins [11]. CRB1 is expressed in retina and brain
and is highly homologous to the Drosophila melanogaster
Crumbs (crb) protein [1,12]. In the mouse retina, CRB1 is
located in the apical region of retinal pigment epithelial
(RPE) cells, rod and cone photoreceptor cells and Muller
glial cells [13]. In this way, the Drosophila Crumbs loss-
of-function (LOF) mutant leads to similar photoreceptor
defects to those observed in patients carrying CRB1 muta-
tions [11]. Both human and fly proteins seem to play an es-
sential role in photoreceptor morphogenesis, including
maintenance of the polarity of RPE cells [13,14].
Preliminary studies in the Spanish population have
shown CRB1 as the main mutated gene in LCA patients
(17%) [15] but it seems to explain only about 2% of EORP
[16]. In both studies, a commercial APEX (Arrayed Pri-
mer EXtension)-based microarray for LCA or arRP was
used to genotype previously known CRB1 mutations.
Therefore it is likely that the real impact of CRB1
mutations is underestimated. Some Spanish cases had
previously studied for CRB1 mutations using several mu-
tational scanning methods such as single-strand confor-
mational polymorphism analysis (SSCP) or denaturing
high-performance liquid chromatography (dHPLC) [5,15],
which are expensive and technically time-consuming. By
contrast, the recently developed high resolution melting
(HRM) analysis allows a simple, semi-automated, and
cost-effective detection of single-base substitutions and
small insertions/deletions [17].Here, with the aim of investigating the prevalence of
CRB1 mutations in the Spanish population, we performed
a comprehensive screening of CRB1 mutations in a large
cohort of Spanish LCA/EORP patients using different in-
direct and direct molecular approaches in a sequential
way. HRM scanning and Sanger sequencing were mainly
used to find novel CRB1 disease alleles in patients in
whom no mutation was identified by a preliminary micro-
array genotyping.
Methods
Participants and clinical evaluation
Patients diagnosed with LCA or EORP were recruited
from Fundación Jiménez Díaz Hospital (FJD, Madrid,
Spain) from 1990 to 2011. Informed consent was obtained
from all subjects prior to their participation in this study.
All procedures were reviewed and approved by the Ethics
Committee of the hospital and adhered to the tenets of
the Declaration of Helsinki.
Clinical diagnosis of RD was based on measurements of
visual acuity and visual field tests, fundus examination and
electroretinogram (ERG) responses. Diagnostic criteria of
LCA included: 1) severe visual loss from birth or before
1 year of age; 2) congenital nystagmus; 3) sluggish or absent
pupillary responses and 4) non-recordable or significantly
reduced ERG. Diagnostic criteria of EORP included poor
night vision and/or peripheral visual loss in childhood, with
poor visual acuity and visual field loss in advanced stages of
the pathology. Patients with family pedigree compatible
with autosomal dominant or X-linked inheritance or with
any systemic sign underlying syndromic forms of retinal
dystrophy were excluded.
A total of 404 unrelated Spanish families with autosomal
recessive or isolated retinal dystrophy were selected: 114
families with LCA and 290 families with EORP. Genomic
DNA was obtained from peripheral blood samples from
FJD Biobank using an automated DNA extractor (BioRobot
EZ1 Qiagen, Hilden, Germany) following the manufac-
turer instructions.
Previously, 23 of these 404 patients were studied for
CRB1 mutations by SSCP as described by Bernal et al.
[5]. Two of them were found to carry pathogenic var-
iants in CRB1 and were included in the summaries pre-
sented herein.
One hundred sixty-five healthy unrelated Spanish indi-
viduals without personal or familial history of retinal
dystrophy were screened as controls to evaluate the fre-
quency of the novel variants.
Mutation detection by APEX microarray
Index cases of the 404 families were screened for known
mutations to cause LCA or autosomal recessive RP (arRP)
using a commercial genotyping chip based on APEX tech-
nology (LCA or ARRP chip, Asper Ophthalmics, Tartu,
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rare variants in the CRB1 gene. All variants identified by
the previous methodology were further validated by Sanger
sequencing and, whenever DNA was available, familial seg-
regation was verified. In cases when only one allele was
identified in the CRB1 gene, microsatellite analysis and/or
direct mutational screening by dHPLC, HRM or Sanger
sequencing was used in order to detect the presence of a
second pathogenic variant.
Mutation scanning by dHPLC and HRM analysis
Exons and exon-intron boundaries of CRB1 (RefSeq
NM_201253) were analysed using 25 oligonucleotide pri-
mer pairs designed by Hanein et al., 2004 or specifically
designed using Primer3 software http://primer3.wi.mit.
edu/, as detailed in Additional file 1: Table S1.
After standard PCR amplification, dHPLC analysis was
performed with the WAVE DNA fragment analysis sys-
tem (Transgenomic) as previously reported [5,15,18].
A HRM approach was specifically developed and
optimised for mutational scanning of the CRB1 gene.
Real-time PCR and HRM were consecutively done on a
LightCycler 480 Real-Time PCR System (Roche) in one
single run, and all reactions were performed in duplicate.
PCR amplifications were done in the presence of
2.5 mmol/L MgCl2 according to the protocols provided
by Roche. PCR conditions were: 95°C for 10 minutes,
followed by 45 cycles of pre-incubation at 95°C for
20 seconds, annealing for 20 seconds at the indicated
temperature in Additional file 1: Table S1 and extension
at 72°C for 20 seconds. After amplification, PCR pro-
ducts were denatured at 95°C for 1 minute and cooled
down to 40°C to allow hetero-duplex formation. The
final HRM step was performed from 40°C to 95°C with
an increase of 1°C/s with 25 acquisitions/°C. The HRM
curve analysis was performed using the LightCycler 480
Gene Scanning Software (Roche). Melting curves were
normalized, temperature-adjusted and finally, a differ-
ence plot was generated.
For methodological optimization, HRM analysis was fur-
ther applied on both control samples and mutated patients
carrying previously identified CRB1 genetic variants by
Sanger sequencing. As the majority of known alleles in
CRB1 are located in exons 2, 7 and 9, we first analysed 5
different variants in these exons by HRM: c.498_506del on
amplicon 2b, c.2244-47delATC on amplicon 7a, c.2290C>T
and c.2307C>T on amplicon 7b; c.2843 G>A on amplicon
9a. Melting curves generated from these amplicons
allowed an easy discrimination of all these variants, except
the change in exon 9a coding for the most prevalent mu-
tation, p.Cys948Tyr that could not be detected (Additional
file 2: Figure S1).
Two hundred twenty-five index cases were screened by
HRM analysis. All amplicons were further sequenced todiscriminate not only disease-causing mutations and be-
nign polymorphisms but also false positive and false nega-
tive HRM profiles. Sensitivity and specificity of HRM
scanning to identify CRB1 mutations were also calculated
using Sanger sequencing as gold standard.
Sanger sequencing
PCR products were enzymatically purified using ExoSAP-it
(USB, Affymetrix) and sequenced on both strands using
the Big Dye Terminator Cycle Sequencing Kit v3.1 Kit
(Applied Biosystems). The sequence products were purified
on a 96-well multiscreen filter plate (Montage SEQ96 Se-
quencing Reaction Cleanup Kit, Millipore, Bedford, MA)
and resolved on an automated sequencer (ABI 3130xl
Genetic Analyzer, Applied Biosystems).
Indirect analysis
Microsatellite analysis was performed in 80 families using
flanking polymorphic markers (TEL-D1S408, D1S2757,
D1S2816, D1S1660-CEN), as previously described [15].
After carrying out the PCR amplification, fluorescent-
labelled products were analysed in an automatic sequen-
cer (3130xl ABI Prism, Applied Biosystems, CA, USA).
Whole genome homozygosity mapping was performed
in 66 consanguineous and non-consanguineous families
using high-resolution commercial SNP arrays from Affy-
metrix (Genome Wide Human SNP array 6.0 and Gene-
Chip Human Mapping 500 K Array Set) or Illumina
(HumanLinkage V Panel Set or Omni Whole Genome
arrays HumanCytoSNP-12). Arrays were processed accor-
ding to the manufacturer protocols. Affymetrix genotyping
services were provided by the Spanish National Geno-
typing Center (CEGEN-ISCIII)”. Homozygosity regions
were calculated using using the Linkage Disequilibrium -
Hidden Markov Model algorithm (LD-HMM) [19] through
the dCHIP software [20].
MLPA Analysis
Multiplex Ligation-dependent Probe Amplification (MLPA)
was performed to discard large deletions or duplications
in patients carrying only one CRB1 allele after the above
molecular screening. The commercial P221 LCA mix-1
SALSA MLPA kit (MRC Holland, Amsterdam, Nether-
lands) that contains specific probes for all exons of the
CRB1 gene, except for exon 11, was used according to the
manufacturer recommendations. The amplified fragments
were separated by capillary electrophoresis using an ABI
3130xl automatic analyser (Applied Biosystems).
Assessment of the pathogenicity of new and unclassified
variants
Pathogenicity of unreported variants was established by
the following criteria: 1) co-segregation in the family, 2)
absence in 165 Spanish healthy control individuals, 3)
Table 1 General description of patients and molecular tools included in this study























114 LCA 8 /114 4 / 8 a 12 (10%) 0 / 20 1 b/43 1 / 3 1 / 32 1 / 32 0 / 1 1/51 16 (14%) 32 (28%)
290 EORP 6 /290 15 /25 a 21 (7%) 0 / 60 0 / 23 1 / 20 0 / 193 1 / 193 1 / 1 c 4 d/ 209 27 (9%) 59 (20%)
404 Total 14 / 404 19 /33 33 (8%) 0 / 80 1 / 66 2 / 23 1 / 225 2 / 225 1 / 2 5/ 260 43 (11%) 91 (22%)
Overview of the sequential steps performed during the mutational CRB1 analysis in a cohort of LCA and EORP Spanish patients was reflected. The number of cases characterized and studied is outlined for each
molecular tool. APEX: Arrayed primer extension; IBD: Inherited-by-descent; SSCP: single-strand conformation polymorphism analysis; HRM: High resolution melting analysis. * A direct mutational scanning of CRB1 was
performed using dHPLC, HRM or Sanger sequencing in patients with a first allele identified by APEX microarray. & SSCP findings were reported by Bernal S. et als, 2003. # Mutations in another gene were found by
APEX microarray, whole-genome homozygosity maping, whole exome sequencing or targeted NGS (data not shown).
a A second CRB1 allele was not found in 14 patients: 2 carried a known frameshift mutation and 12 carried a uncertain or very unlikely missense variant.
b A 5 Mb-homozygous region involving CRB1 was identified in an endogamic family and a homozygous known mutation was further found by Sanger sequencing. This mutation represents a false negative of the
previously LCA chip analysis.
c A second allele (c.1702C>T) was further found by Sanger sequencing, representing a false negative of the HRM analysis.
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genicity prediction with in silico tools, and 5) presence of a
second pathogenic allele. These criteria were applied to
the new variants found in this study as well as for previ-
ously unclassified missense variants.
Amino acid conservation was determined using 17
orthologs of the CRB1 protein belonging to different evo-
lutionary branches (Chimpanzee, Marmoset, Rhesus
Macaque, Orangutan, Gibbon, Cow, Rat, Mouse, Rabbit,
Dog, Horse, Wild boar, Opossum, Turkey, Lizard, Frog
and Zebrafish). BLINK tool (http://www.ncbi.nlm.nih.gov/
sutils/blink.cgi?pid=6014482) and Jalview Alignment Edi-
tor program (http://www.jalview.org/) were used to ana-
lyse the multiple sequence alignments. If a residue did not
change throughout the species it was considered “highly
conserved”, if a residue was present in less than 3 species
it was considered “moderately conserved”, if it was present
in 3–5 ortholog proteins, it was considered “weakly con-
served”, otherwise it was classified as “non conserved”.
Deleterious effects of amino acid substitutions on protein
function were assessed using different bioinformatic pro-
grams, including Align-GVGD (http://agvgd.iarc.fr/agvg-
d_input.php), PolyPhen-2 (Polymorphism Phenotyping
v2) (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://
sift.jcvi.org/) and Protein Variation Effect Analyzer
(PROVEAN) (http://provean.jcvi.org/index.php). Splice-
site mutations were analysed with the Human Splicing
Finder (HSF) tool (http://www.umd.be/HSF/).
Results
DNA samples from 404 Spanish index cases with LCA or
EORP were first analysed using the LCA/ARRP chips in
order to identify known mutations, followed by further
screening of CRB1 mutations using several indirect and
direct strategies, such as homozygosity mapping, HRM
analysis and Sanger sequencing, as summarized in
Table 1.
Two causative variants were found in the 11% (43 / 404)
of our Spanish patients (Table 2). Considering the two dif-
ferent phenotypes studied, 14% of LCA and 9% of early-
onset RP patients carried CRB1 mutations (Additional file
2: Figure S2, S3 and S4). A pathogenic CRB1 allele was also
identified in 2 additional patients but a second variant
could not be identified by whole screening of this gene by
Sanger sequencing and MLPA (Table 2). Heterozygous
missense variants with very unlikely pathogenic implication
(Additional file 1: Table S2 and Additional file 2: Figure S5)
were found in other 13 patients.
The molecular analysis of CRB1 revealed 34 different
mutations in 45 Spanish LCA/EORP patients, as detailed
in Additional file 1: Table S3. Most of the disease alleles
were in exons 9 (43%), 7 (19%) and 2 (16%). Therefore,
76% (26 / 34) of the mutations, representing 55% of the
total CRB1 alleles, have been first described in thiscohort (Table 3). Compound heterozygous CRB1 muta-
tions were found in all cases except for 9 families with
known inbreeding or endogamic history. The most fre-
quent mutation representing the 22% of CRB1 alleles
was p.Cys948Tyr identified in 16 families. This mutation
was in heterozygous state in all cases except for 3 homozy-
gous patients. The variants p.Ile1100Thr and c.498_506del
that were first identified in our cohort, are also quite com-
mon with a frequency of 9 and 8%, respectively. Similarly,
other mutations such as p.Asp564Tyr, p.Ile1001Asn and
p.Glu1330* were present in more than one family
(Additional file 1: Table S3).
A total of 15 novel variants were identified during the
current screening of CRB1: 4 missense variants, 4 non-
sense mutations, 3 frameshift indels and 2 splicing-site
mutations (Table 3, Additional file 1: Table S2).
Pathogenicity of the novel variants was assessed by
co-segregation with a second disease allele on the
CRB1 gene whenever family members were available
(Additional file 2: Figures S2, S3 and S4) and by ab-
sence in 330 healthy Spanish control chromosomes.
None of the novel variants were described as poly-
morphic changes in the dbSNP database or the litera-
ture. All mutations described herein were submitted
to the existing Locus Specific Databases (LSDB) on
CRB1. The novel missense mutations affected conserved
residues of the CRB1 protein (Additional file 2: Figure S5)
and were classified as likely damaging by in silico predic-
tion tools (Table 3).
Discussion
Mutations in CRB1 are a common cause of congenital
or severe childhood-onset RD accounting for up to
10.1% of LCA/EORD patients and 2.7% in RP cases, as
described in a recent meta-analysis of CRB1 mutations
[10]. The above frequencies may be underestimated, as
sequencing of entire coding regions had not been sys-
tematic performed. In this sense, CRB1 analysis in large
cohorts of patients has been mostly performed by us and
other groups using SSCP or chip-based screening
for known RD mutations [3-5,8,10,15,16,21]. Only
Coppieters et als performed a subsequent an exhaustive
screening of CRB1 and other LCA-related genes by San-
ger sequencing in all patients with negative chip results
obtaining a higher frequency (16%) of CRB1 mutations
[22]. Similarly, we aimed to evaluate herein the real rele-
vance of CRB1 mutations in the Spanish population
using an additional comprehensive mutational screening
by HRM and Sanger sequencing, identifying causative
variants in 11% of LCA/EORP cases. It is noteworthy
that we found a high number of private CRB1 mutations
in our cohort confirming the usefulness of in-depth
CRB1 genetic analysis to identified novel variants un-
detectable by genotyping microarrays.
Table 2 Patients carrying CRB1 mutations identified in this study
Family Allele 1 Allele 2 References Methods Phenotype
Exon Nucleotide Change AA Change Exon Nucleotide Change AA Change
LCA-0010 2 c.481dupG p.Ala161Glyfs*8 2 c.481dupG p.Ala161Glyfs*8 [5] chip LCA
RP-0091 2 c.481dupG p.Ala161Glyfs*8 ? ? [5] chip + seq EORP
RP-1426 2 c.498_506del p.Ile167_Gly169del 2 c.498_506del p.Ile167_Gly169de [21] seq EORP
RP-1611 2 c.498_506del p.Ile167_Gly169del 5 c.1147_1156del p.Cys383Serfs*66 [21], Novel chip + seq EORP
RP-2004 2 c.498_506del p.Ile167_Gly169del 7 c.2234C > T p.Thr745Met [21] [1] chip + seq EORP
RP-0745 2 c.498_506del p.Ile167_Gly169del 7 c.2290C > T p.Arg764Cys [21] [1] chip + HRM EORP
RP-0243 2 c.498_506del p.Ile167_Gly169del 8 c.2688 T > A p.Cys896* [21] [22] chip + dHPLC EORP
MD-0092b 2 c.498_506del p.Ile167_Gly169del 9 c.2843G > A p.Cys948Tyr [21] [1] chip + HRM EORP
LCA-0019 2 c.613_619del p.Ile205Aspfs*13 7 c.2227delG p.Val743Serfs*11 [2] [23] chip + dHPLC EORP
LCA-0051 2 c.613_619del p.Ile205Aspfs*13 9 c.2843G > A p.Cys948Tyr [2] [1] chip EORP
LCA-0063 2 c.613_619del p.Ile205Aspfs*13 11 c.4005 + 1G > A Splicing [2] [22] chip EORP
RP-1311 2 c.613_619del p.Ile205Aspfs*13 ? ? [2] chip + seq EORP
LCA-0032 6 c.1604 T > C p.Leu535Pro 9 c.2843G > A p.Cys948Tyr [15] [1] chip + seq LCA
LCA-0099 6 c.1690G > T p.Asp564Tyr 8 c.2688 T > A p.Cys896* [15] [22] chip LCA
LCA-0038b 6 c.1690G > T p.Asp564Tyr 9 c.3002 T > A p.Ile1001Asn [15] seq EORP
RP-1535 6 c.1690G > T p.Asp564Tyr 9 c.3014A > T p.Asp1005Val [15], Novel chip + seq EORP
RP-1504 6 c.1702C > T p.His568Tyr 12 c.4142C > T p.Pro1381Leu Novel [6] HRM + seq EORP
RP-1586 7 c.2234C > T p.Thr745Met 7 c.2234C > T p.Thr745Met [1] chip EORP
RP-1017 7 c.2234C > T p.Thr745Met 7 c.2416G > T p.Glu806* [1] Novel chip + seq EORP
MD-0643 7 c.2234C > T p.Thr745Met 9 c.2843G > A p.Cys948Tyr [1] chip EORP
RP-0561 7 c.2234C > T p.Thr745Met 11 c.3988G > T p.Glu1330* [1] [24] chip + dHPLC EORP
LCA-0011 7 c.2244_47delATC p.Ser749del 9 c.2843G > A p.Cys948Tyr [5] [1] chip LCA
RP-1779 7 c.2290C > T p.Arg764Cys 9 c.3299 T > C p.Ile1100Thr [1] [5] chip EORP
RP-0487 7 c.2290C > T p.Arg764Cys 11 c.3988G > T p.Glu1330* [1] [24] chip + dHPLC EORP
RP-1689 7 c.2291G > A p.Arg764His 12 c.4168C > T p.Arg1390* Novel seq EORP
LCA-0060 7 c.2309G > T p.Gly770Val 8 c.2805dupA p.His935Glnfs*13 Novel HRM LCA
LCA-0017 7 c.2401A > T p.Lys801* 7 c.2401A > T p.Lys801* [4] IBD mapping LCA
RP-0280 7 c.2465G > A p.Trp822* 9 c.2843G > A p.Cys948Tyr [15] [1] chip + dHPLC EORP
LCA-0004 8 c.2688 T > A p.Cys896* 9 c.2843G > A p.Cys948Tyr [22] [1] chip LCA
LCA-0038a 8 c.2688 T > A p.Cys896* 9 c.3002 T > A p.Ile1001Asn [22] [15] chip + dHPLC LCA




















Table 2 Patients carrying CRB1 mutations identified in this study (Continued)
RP-0069a 9 c.2843G > A p.Cys948Tyr 9 c.2843G > A p.Cys948Tyr [1] SSCP LCA
MD-0092a 9 c.2843G > A p.Cys948Tyr 9 c.2843G > A p.Cys948Tyr [1] chip EORP
MD-0351 9 c.2843G > A p.Cys948Tyr 9 c.3157 A > G p.Met1053Val [1] Novel chip + HRM EORP
RP-1625 9 c.2843G > A p.Cys948Tyr 9 c.3157A > G p.Met1053Val [1] Novel chip + HRM EORP
LCA-0028 9 c.2843G > A p.Cys948Tyr 9 c.3299 T > C p.Ile1100Thr [1] [5] chip LCA
RP-1558 9 c.2843G > A p.Cys948Tyr 9 c.3607G > T p.Glu1203* [1] Novel chip + seq EORP
LCA-0027 9 c.2843G > A p.Cys948Tyr 11 c.3988G > T p.Glu1330* [1] [24] chip + seq LCA
LCA-0038c 9 c.3002 T > A p.Ile1001Asn 9 c.3482A > G p.Tyr1161Cys [15] [25] seq EORP
LCA-0101 9 c.3152G > A p.Trp1051* 11 c.4000delG p.Val1334Trpfs*7 Novel seq LCA
RP-0069b 9 c.3299 T > C p.Ile1100Thr 9 c.2843G > A p.Cys948Tyr [5] [1] SSCP EORP
RP-0025 9 c.3299 T > C p.Ile1100Thr 9 c.3299 T > C p.Ile1100Thr [5] chip EORP
RP-1212 9 c.3299 T > C p.Ile1100Thr 9 c.3299 T > C p.Ile1100Thr [5] chip EORP
RP-1615 9 c.3299 T > C p.Ile1100Thr 9 c.3749 + 1_3749 + 2delGT Splicing [5] Novel chip + seq EORP
RP-1440 10 c.3878 + 2insT a Splicing 8 c.2696G > C p.Gly899Ala Novel chip + HRM EORP
Mutations in bold correspond to variants first described in our cohort. Nucleotide numbering reflects cDNA in the reference sequence NM_201253.1, according to journal guidelines (www.hgvs.org/mutnomen). The
initiation codon is codon 1. Different molecular approaches were used to identify both pathogenic alleles. C: APEX microarray, S: Sanger sequencing, D: dHPLC, denaturing high-performance liquid chromatography
analysis, H, HRM: high-resolution melting analysis, IBD: Inherited-by-descent mapping, performing using whole-genome SNP arrays; ?: Second allele not found after Sanger sequencing and MLPA analysis;
a Unexpected signal on APEX array was detected at the interrogated nucleotide c.3878 + 2 further confirming as a novel heterozygous insertion by Sanger sequencing.




















Table 3 List of novel CRB1 likeky pathogenic variants identified in the studied cohort











c.1604 T > C p.Leu535Pro Lam AG1 HC 0 1 Class C65 −6.5 Likely
c.1690G > T p.Asp564Tyr Lam AG1 HC 0 1 Class C65 −8.2 Likely
c.1702C > T p.His568Tyr Lam AG1 HC 0 0.999 Class C65 −5.0 Likely
c.2291G > A p.Arg764His Lam AG2 NC 0.06 0.012 Class C0 −2.3 Uncertain a
c.2309 G > T p.Gly770Val Lam AG2 HC 0 1 Class C65 −8.2 Likely
c.2696 G > C* p.Gly899Ala EGF13 HC 0.1 0.996 Class C0 −4.5 Likely
c.3002A > T p.Ile1001Asn Lam AG3 MC 0.0 0.850 Class C45 −5.5 Likely
c.3014 A > T p.Asp1005Val Lam AG3 WC 0.02 0.996 Class C15 −5.0 Likely
c.3157 A > G p.Met1053Val Lam AG3 HC 0 0.994 Class C15 −2.2 Likely
c.3299 T > C p.Ile1100Thr Lam AG3 C 0 0.977 Class C25 −3.6 Likely
c.3482A > G p.Tyr1161Cys EGF15 MC 0 0.999 Class C15 −6.1 Likely
Nonsense
c.2416G > T p.Glu806* Lam AG2 Protein truncation, NMD
c.2465G > A p.Trp822* Lam AG2 Protein truncation, NMD
c.3152G > A p.Trp1051* Lam AG3 Protein truncation, NMD
c.3607 G > T p.Glu1203* EGF16 Protein truncation, NMD
c.3988G > T p.Glu1330* EGF19 Protein truncation, NMD
c.4168C > T p.Arg1390* C Protein truncation
Frameshift indels
c.481dupG p.Ala161Glyfs*8 EGF4 Protein truncation, NMD
c.1147_1156del p.Cys383Serfs*66 EGF9 Protein truncation, NMD
c.2227delG p.Val743Serfs*11 Lam AG2 Protein truncation, NMD
c.2805dupA p.His935Glnfs*13 EGF14 Protein truncation, NMD
c.4000delG p.Val1334Trpfs*7 EGF19 Protein truncation, NMD
Splicing
c.3749 + 1_3749 + 2del - EGF17 Splicing defect, NMD




















Table 3 List of novel CRB1 likeky pathogenic variants identified in the studied cohort (Continued)
In-frame indel
c.2244_47delATC p.Ser749del Lam AG2 WC −11.453 Likely
c.498_506del p.Ile167_Gly169del EGF4 Gly167: MC −14.258 Likely
Nucleotide numbering is based on RefSeq DNA accession number NM_201253.1. Lam AG: Laminin AG-like domain, EGF: EGF-like domain, C: cytoplasmatic domain. Conservation of the amino acid substituted or
deleted in 17 species was detailed. HC: Highly conserved, MC: Moderately conserved, WC: Weakly conserved, and NC: non-conserved residue. The amino acid substitution is predicted damaging by if the SIFT score is
< = 0.05 and PROVEAN scores is < −2.5. Polyphen predict a non-synonymous variant as benign, possibly damaging, or probably damaging, if score is < 0.2, between 0.2 and 0.85 or > 0.85. GV: Grantham Variation; GD:
Grantham distribution. Class C65: most likely pathogenic, Class C0: less likely pathogenic.
a This variant has been considered as likely pathogenic despite of poor conservation and less likely pathogenicity with four predictive tools. This variant was found associated with a second allele. It was absent in
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CRB1 mutations in RP patients [6] [8] [10]. CRB1 defects
seemed to explain <3% of EORP cases as described in our
previous reports in Spanish patients [15,16] and other
population [8,10]. However, it is remarkable that herein up
to 9% of our EORP patients carried two CRB1 mutations.
We presumed that this improved detection rate of CRB1
variants could be due not only to the use of an updated
arRP microarray containing some mutations first described
in the Spanish population but also for carrying out a com-
prehensive analysis of the whole gene. Although the most
frequent mutation in EORP patients is p.Cys948Tyr occur-
ring worldwide [7], it is noteworthy that 25% of pathogenic
CRB1 alleles correspond to 2 apparently population-
specific mutations, the c.498_506del and p.Ile1100Thr va-
riants [10]. In fact, 19 of 25 different EORP-associated
CRB1 mutations, representing 61% of CRB1 alleles, were
first identified in our cohort, that evidences a high fre-
quency of population-specific mutations in the Spanish
EORP patients.
Focusing on the LCA patients, CRB1 defects accounted
for 14% of Spanish cases. In view of the high detection rate
obtained, APEX genotyping seems to be a quite effective
and fast diagnostic approach to detect CRB1 mutations in
our LCA cohort. However, 4 additional patients were iden-
tified carrying novel mutations by a further CRB1 complete
screening. The frequency of CRB1 mutations varies among
different studies, ranging from 1% in a cohort of LCA
patients hailing from worldwide countries [23] to 16% in
Belgium [22]. Although the prevalence of CRB1 defects is
apparently identical between the Belgian and Spanish co-
horts, substantial differences are evidenced in the muta-
tional CRB1 spectrum. The missense variant p.Cys948Tyr
is also the most frequent disease allele in Spanish LCA
patients, representing 31% of total alleles, but not in
Belgium being less prevalent with a frequency of 23% [22].
In contrast, the most recurrent allele in Belgian patients,
p.Lys801*, was only detected in one Spanish LCA case.
Interestingly, 12 out 17 different LCA-associated CRB1
variants, representing 44% of total alleles, seem to be spe-
cific to our cohort.
Mutations in CRB1 were previously associated with a
wide range of phenotypic manifestations [1-6,23]. Complete
loss of function of the CRB1 protein seems to be more
related with development of LCA phenotype, while some
residual functionality may remain in childhood-onset pa-
tients [9]. Nevertheless, a clear genotype–phenotype cor-
relation could not be established since 2 seeming LOF
alleles were not only identified in LCA but also EORD in
several cohorts [8]. Interestingly, we observed that a com-
bination of 2 null mutations was only found in about 40%
of LCA patients but in none of our EORP patients, as
showed in Additional file 2: Figure S6. Null alleles were
significantly more frequent in LCA that in EORP patients(χ2 = 10.2, p<0.001), as previously suggested [8]. However,
a similar proportion of LCA and EORP cases carried a
combination of null-allele with missense mutation and sev-
eral LCA patients also presented 2 missense alleles, being
p.Cys948Tyr always involved. In consequence, it is not
easy to assign a specific allele combination to a particular
phenotype, suggesting a strong influence of environmental
factors or genetic modifiers on the severity of the disease.
In fact, it is likely that the new next-generation sequencing
(NGS) technology will help to identify potential genetic
variants that modulate LCA and EORP phenotypes asso-
ciated to CRB1 defects.
In view of the high frequency of compound heterozy-
gous variants in CRB1, we evaluated the HRM technology
that is considered a powerful approach to efficiently dis-
criminate heterozygous variants [17], as an alternative to
Sanger sequencing. We accurately identified heterozy-
gous variants in all abnormal melting curves (specificity of
100%); however, we also found 4 false negatives thus ob-
taining a lower sensitivity of 73% for CRB1 screening by
HRM. Several factors such as amplicon size or GC content
could influence the sensitivity to detect melting variants
and explain the unexpected high number of false negatives
in this analysis as opposed to previously reports [24].
This work supports the importance of comprehensive
genetic studies in order to ascertain the real prevalence of
retinal gene defects in large cohorts of well-clinically phe-
notyped patients. Main limitations to in-depth genetic
analysis of RD are related to the use of expensive and
time-consuming techniques. However the recent advances
in NGS technologies and their progressive implementa-
tion in the clinical diagnosis will help to improve the mo-
lecular diagnosis and also to shed light on genetics of
retinal dystrophies.
Conclusions
This study has allowed us to establish gene-specific fre-
quencies in our population. It is worth to note that, to our
knowledge, this study represents the most complete mu-
tational screening of CRB1 in an early-onset RP cohort.
Recently, two large studies of the prevalence of CRB1
mutations have been published; however the whole gene
has not been analyzed in most of the cases [6,10]. By con-
trast, we performed an additional scanning of CRB1 using
an optimized HRM strategy and/or Sanger sequencing. In
summary, CRB1 defects represent a very common cause
of LCA and early-onset RP in the Spanish population.
Additional files
Additional file 1: Table S1. Primers and conditions used for
conventional PCR and real-time PCR. * Redesigned primer. Table S2. In
silico Predictions of Unlikely Pathogenic Non-Synonymous CRB1 Variants.
Novel variants are in bold. Nucleotide numbering is based on RefSeq
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http://www.ojrd.com/content/8/1/20DNA accession number NM_201253.1. Lam AG: Laminin AG-like domain,
EGF: EGF-like domain, Conservation of the amino acid substituted or
deleted in 17 species was detailed. HC: Highly conserved, MC: Moderately
conserved, WC: Weakly conserved, and NC: non-conserved residue. The
amino acid substitution is predicted damaging by if the SIFT score is <=
0.05 and PROVEAN scores is < −2.5. Polyphen predict a non-synonymous
variant as benign, possibly damaging, or probably damaging, if score is <
0.2, between 0.2 and 0.85 or > 0.85. GV: Grantham Variation; GD:
Grantham distribution. Class C65: most likely pathogenic, Class C0: less
likely pathogenic. Table S3. Overview of Likely Pathogenic Mutations
Identified in this Study.
Additional file 2: Figure S1. Normalized melt curves and difference
plots of five CRB1 variants used for standardization. Blue curves represent
wild-type HRM profiles, except for the p.Cys948Tyr variant. Figure S2.
Segregation Analysis of CRB1 Mutations in Characterized Families with
Leber Congenital Amaurosis. The CRB1 genotype of each available family
member is represented below the individual symbol being “+” wild type
allele, m, m1 and m2 mutated alleles. Haplotype analysis was performed
with markers flanking the CRB1 gene (CEN-D1S408-D1S2757- D1S2816-
D1S1660-TEL). Nucleotide numbering reflects cDNA numbering in the
reference sequence NM_201253.1, according to journal guidelines (www.
hgvs.org/mutnomen). The initiation codon is codon 1 &: Two distinct
retinal dystrophies with mutations affecting 2 different genes
cosegregated in this family as previously reported by Riveiro-Alvarez, R.
2008. Patient II:2 exhibited Stargardt disease and carried a homozygous
mutation (c.5413A>G; p.Asn1805Asp) in ABCA4. However, individual IV:4
presented an early-onset RP that is explained by the presence of two
CRB1 mutations. Figure S3. Segregation Analysis of CRB1 Mutations in
Characterized Families with Early-Childhood-Onset RP. The CRB1
genotype of each available family member is represented below the
individual symbol being “+” wild type allele, m, m1 and m2 mutated
alleles. Haplotype analysis was performed with markers flanking the CRB1
gene (CEN-D1S408-D1S2757- D1S2816-D1S1660-TEL). Nucleotide
numbering reflects cDNA in the reference sequence NM_201253.1,
according to journal guidelines (www.hgvs.org/mutnomen). The initiation
codon is +1. Figure S4. Pedigrees and segregation analysis of families
segregating both Leber Congenital Amaurosis and Early-Childhood-Onset
RP phenotypes. LCA and early-onset RP phenotypes have been found in
the same pedigree caused by different combination of distinct CRB1
alleles. The CRB1 genotype of each available family member is
represented below the individual symbol being “+” wild type allele, m,
m1, m2, m3 and m4 mutated alleles. Haplotype analysis was performed
with markers flanking the CRB1 gene (CEN-D1S408-D1S2757- D1S2816-
D1S1660-TEL). Nucleotide numbering reflects cDNA numbering in the
reference sequence NM_201253.1, according to journal guidelines (www.
hgvs.org/mutnomen). The initiation codon is +1. Figure S5. Evolutionary
conservation of the novel missense mutation in the CRB1 protein. We
considered the following 18 species: Human, Chimpanzee (Pan
troglodytes), Marmoset (Callithrix jacchus), Rhesus Macaque (Macaca
mulatta), Orangutan (Pongo abelii), Gibbon (Nomascus leucogenys), Cow
(Bos taurus), Rat (Rattus norvegicus), Mouse (Mus musculus), Rabbit
(Oryctolagus cuniculus), Dog (Canis lupus familiaris), Horse (Equus caballus),
Wild boar (Sus scrofa), Opossum (Monodelphis domestica), Turkey
(Meleagris gallopavo), Lizard (Anolis carolinensis), Frog (Xenopus tropicalis),
Zebrafish (Danio rerio). Residues on a dark blue background are fully
conserved between different species. Residues coloured light blue are
similar to amino acid residues in other orthologs. Figure S6. Genotype–
phenotype correlation of patients with CRB1 mutations. Frequency of
different combination of null alleles, missense variants and in-frame
deletions in LCA and EORP patients.
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